The European approach to in-transit melanoma lesions

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International Journal of Hyperthermia

• Publication date

  2008-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/02656730701816402PMID 18393001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology

  2009cited by this paper
• TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial

  2008cited by this paper
• Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines

  2007cited by this paper
• Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.

  2007cited by this paper
• Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.

  2007cited by this paper
• Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial

  2006cited by this paper
• Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.

  2006cited by this paper
• Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

  2006cited by this paper
• Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma

  2006cited by this paper
• Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients

  2006cited by this paper
• TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

  2006cited by this paper
• The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.

  2005cited by this paper
• Follow-up in patients with localised primary cutaneous melanoma.

  2005cited by this paper
• Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy)

  2005cited by this paper
• Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure

  2005cited by this paper
• One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases

  2004cited by this paper
• Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma.

  2004cited by this paper
• Cutaneous malignant melanoma in Europe.

  2004cited by this paper
• Isolated limb perfusion for unresectable melanoma of the extremities.

  2004cited by this paper
• Ten‐year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma

  2004cited by this paper
• Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

  2004cited by this paper
• Is Sentinel Lymph Node Mapping Indicated for Isolated Local and In-Transit Recurrent Melanoma?

  2003cited by this paper
• Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma

  2002cited by this paper
• Safety and efficacy of isolated limb perfusion in elderly melanoma patients

  2002cited by this paper
• Continuous Leakage Measurement During Hyperthermic Isolated Limb Perfusion

  2001cited by this paper
• Educational tips in the treatment of malignant ulcerating tumours of the skin.

  2000cited by this paper
• Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

  2000cited by this paper
• Hyperthermic isolated regional perfusion of the limb with carboplatin.

  2000cited by this paper
• Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

  1999cited by this paper
• Are Locoregional Cutaneous Metastases in Melanoma Predictable?

  1999cited by this paper
• Management of Extremity Recurrences After Complete Responses to Isolated Limb Perfusion in Patients With Melanoma

  1999cited by this paper
• Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.

  1998cited by this paper
• Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ

  1998cited by this paper
• Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a

  1998influential reference
• Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics

  1997cited by this paper
• Frequency and duration of remission after isolated limb perfusion for melanoma.

  1997cited by this paper
• Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma

  1997cited by this paper
• Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology.

  1996cited by this paper
• High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.

  1996cited by this paper
• Isolated limb infusion with melphalan for recurrent limb melanoma : a simple alternative to isolated limb perfusion

  1994cited by this paper
• Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.

  1994cited by this paper
• A retrospective comparative study evaluating the results of a single‐perfusion versus double‐perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb

  1993cited by this paper
• Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment

  1993cited by this paper
• Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.

  1993cited by this paper
• Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

  1992cited by this paper
• Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.

  1991cited by this paper
• Major amputation for advanced malignant melanoma.

  1989cited by this paper
• The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma

  1988cited by this paper
• To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater.

  1988cited by this paper
• Isolated regional perfusion in malignant melanoma of the extremities

  1987cited by this paper
• Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study

  1985cited by this paper
• Improved tissue perfusion during pressure‐regulated hyperthermic regional isolated perfusion in dogs

  1984cited by this paper
• Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

  1982cited by this paper
• Biologic behavior and treatment of intransit metastasis of melanoma.

  1980cited by this paper
• Biologic behavior and treatment of intransit metastasis of melanoma.

  1980cited by this paper
• Selective Heat Sensitivity of Cancer Cells

  1977cited by this paper
• Prevention of neural and muscular lesions during hyperthermic regional perfusion.

  1972cited by this paper
• Prevention of neural and muscular lesions during hyperthermic regional perfusion.

  1972cited by this paper
• Selective heat sensitivity of cancer cells. Biochemical and clinical studies

  1967cited by this paper
• Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit

  1958cited by this paper

• The palliative role of lasers in the treatment of melanoma

  2024cites this paper
• Ultrasound Examination of the Lymphatic Drainage Area and Regional Lymph Nodes in Melanoma Patients with In-Transit Metastases

  2020cites this paper
• Application of CO2 laser evaporation in locally advanced melanoma

  2019cites this paper
• Treatment of Metastatic Melanoma

  2018influential citation
• Regional aspects of melanoma diagnosis and treatment

  2015cites this paper
• Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma.

  2015cites this paper
• CO2 Laser Treatment for Regional Cutaneous Malignant Melanoma Metastases

  2015cites this paper
• Glycosylation Modulates Melanoma Cell α2β1 and α3β1 Integrin Interactions with Type IV Collagen*

  2014cites this paper
• Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review

  2014cites this paper
• Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion?

  2014cites this paper
• In-Transit Intramammary Sentinel Lymph Nodes From Malignant Melanoma of the Trunk

  2012cites this paper
• The Role of Electrochemotherapy in the Treatment of Malignant Melanoma

  2011cites this paper
• Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives

  2011influential citation
• Treatment of Locally Advanced Melanoma by Isolated Limb Infusion with Cytotoxic Drugs

  2011influential citation
• Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.

  2011cites this paper
• Previously Reported Sonographic Appearances of Regional Melanoma Metastases Are Not Likely Due to Necrosis

  2011cites this paper
• Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

  2011cites this paper
• Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging

  2011cites this paper
• Findings that shed new light on the possible pathogenesis of a disease or an adverse effect Cervical in-transit metastasis from a truncal basal cell carcinoma

  2010cites this paper
• Optimal follow-up for melanoma

  2010cites this paper
• Optimal follow-up for

  2010cites this paper
• Metástasis en tránsito de melanoma maligno cutáneo: Reporte de caso y revisión de la bibliografía

  2010cites this paper
• Isolated Limb Infusion

  2009cites this paper
• Monitoring system for isolated limb perfusion based on a portable gamma camera

  2009cites this paper
• The effect of low-level laser irradiation (In-Ga-Al-AsP - 660 nm) on melanoma in vitro and in vivo

  2009cites this paper
• Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

  2009cites this paper